The purpose of this study is to assess the safety and PK characteristics of a single oral dose of HRS-1893 in healthy voluunters.
Study Type
INTERVENTIONAL
Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
20
Single dose of HRS-1893 orally administered
Linear Clinical Research
Nedlands, Western Australia, Australia
PK profile of HRS-1893 after a single oral (PO) administration
Pharmacokinetics PK Cmax: Plasma Cmax
Time frame: Day 8
PK profile of HRS-1893 after a single oral (PO) administration
Pharmacokinetics PK AUClast : Plasma AUClast
Time frame: Day 8
PK profile of HRS-1893 after a single oral (PO) administration
Pharmacokinetics PK AUC0-inf: Plasma AUC0-inf
Time frame: Day 8
PK profile of HRS-1893 after a single oral (PO) administration
Pharmacokinetics PK Tmax :Plasma Tmax
Time frame: Day 8
PK profile of HRS-1893 after a single oral (PO) administration
Pharmacokinetics PK t1/2 : Plasma t1/2
Time frame: Day 8
PK profile of HRS-1893 after a single oral (PO) administration
Pharmacokinetics PK CL/F: Plasma CL/F
Time frame: Day 8
PK profile of HRS-1893 after a single oral (PO) administration
Pharmacokinetics PK Vz/F: Plasma Vz/F
Time frame: Day 8
Cumulative amount of drug excreted in urine of HRS-1893 after a single oral administration
Cumulative amount of drug excreted in urine (Ae,ur)
Time frame: Day 8
Cumulative percentage of dose recovered in urine of HRS-1893 after a single oral administration:
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Cumulative percentage of dose recovered in urine (%Ae,ur)
Time frame: Day 8
Renal clearance of HRS-1893 after a single oral administration
Renal clearance (CLr)
Time frame: Day 8
Safety and Tolerability Based on Incidence and Severity of Treatment Emergent Adverse Events
Number of participants with Adverse events and Serious adverse events
Time frame: Day 8